DE60118430D1 - Behandlung gastrointestinaler stroma-tumoren - Google Patents

Behandlung gastrointestinaler stroma-tumoren

Info

Publication number
DE60118430D1
DE60118430D1 DE60118430T DE60118430T DE60118430D1 DE 60118430 D1 DE60118430 D1 DE 60118430D1 DE 60118430 T DE60118430 T DE 60118430T DE 60118430 T DE60118430 T DE 60118430T DE 60118430 D1 DE60118430 D1 DE 60118430D1
Authority
DE
Germany
Prior art keywords
treatment
gastrointestinal stroma
tumors
stroma tumors
gastrointestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118430T
Other languages
English (en)
Other versions
DE60118430T2 (de
Inventor
Elisabeth Buchdunger
Renaud Capdeville
Daniel Demetri
Sasa Dimitrijevic
J Druker
A Fletcher
Heikki Joensuu
Leta Silberman
David Tuveson
C Heinrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University Portland Us
Novartis AG
Brigham and Womens Hospital Inc
Dana Farber Cancer Institute Inc
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60118430(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60118430D1 publication Critical patent/DE60118430D1/de
Publication of DE60118430T2 publication Critical patent/DE60118430T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60118430T 2000-10-27 2001-10-26 Behandlung von gastrointestinalen stromatumoren Expired - Lifetime DE60118430T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
US243810P 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (2)

Publication Number Publication Date
DE60118430D1 true DE60118430D1 (de) 2006-05-18
DE60118430T2 DE60118430T2 (de) 2006-10-26

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118430T Expired - Lifetime DE60118430T2 (de) 2000-10-27 2001-10-26 Behandlung von gastrointestinalen stromatumoren

Country Status (26)

Country Link
US (1) US6958335B2 (de)
EP (1) EP1332137B1 (de)
JP (1) JP4386635B2 (de)
KR (1) KR100885129B1 (de)
CN (1) CN1276754C (de)
AT (1) ATE321556T1 (de)
AU (2) AU2002218262B2 (de)
BR (1) BRPI0114870B8 (de)
CA (1) CA2424470C (de)
CY (1) CY1105055T1 (de)
CZ (1) CZ303944B6 (de)
DE (1) DE60118430T2 (de)
DK (1) DK1332137T3 (de)
ES (1) ES2260317T3 (de)
HK (1) HK1058193A1 (de)
HU (1) HU229106B1 (de)
IL (2) IL155029A0 (de)
MX (1) MXPA03003703A (de)
NO (1) NO324948B1 (de)
NZ (1) NZ525254A (de)
PL (1) PL209733B1 (de)
PT (1) PT1332137E (de)
RU (1) RU2301066C2 (de)
SK (1) SK287335B6 (de)
WO (1) WO2002034727A2 (de)
ZA (1) ZA200302155B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529145A (en) * 2001-05-16 2005-07-29 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)- 2pyrimidine-amine and a chemotherapeutic agent
ATE343415T1 (de) * 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
WO2003002106A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
EP1401415B1 (de) * 2001-06-29 2006-06-21 AB Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
EP1434991B1 (de) * 2001-06-29 2007-10-17 AB Science C-kit inhibitoren
ATE404202T1 (de) * 2001-09-20 2008-08-15 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
CA2461182A1 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
EP1478380B1 (de) * 2002-02-27 2006-08-02 AB Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
JP2007505859A (ja) * 2003-09-19 2007-03-15 ノバルティス アクチエンゲゼルシャフト イマチニブおよびミドスタウリンでの消化管間質腫瘍の処置
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
WO2008033746A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
JP6006242B2 (ja) 2011-03-04 2016-10-12 ニューゲン セラピューティクス， インコーポレイテッド アルキン置換キナゾリン化合物および使用方法
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
SG11201405099UA (en) 2012-02-21 2014-10-30 Ranbaxy Lab Ltd Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20140235631A1 (en) 2012-07-27 2014-08-21 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
CN115243681A (zh) 2019-12-30 2022-10-25 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2342222A1 (en) * 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Also Published As

Publication number Publication date
SK287335B6 (sk) 2010-07-07
CA2424470C (en) 2009-06-09
AU1826202A (en) 2002-05-06
PL362148A1 (en) 2004-10-18
DE60118430T2 (de) 2006-10-26
SK5182003A3 (en) 2004-02-03
CA2424470A1 (en) 2002-05-02
ATE321556T1 (de) 2006-04-15
JP2004512328A (ja) 2004-04-22
KR100885129B1 (ko) 2009-02-23
KR20030051656A (ko) 2003-06-25
EP1332137A2 (de) 2003-08-06
DK1332137T3 (da) 2006-07-17
CN1276754C (zh) 2006-09-27
PL209733B1 (pl) 2011-10-31
MXPA03003703A (es) 2005-01-25
IL155029A (en) 2009-09-22
BRPI0114870B8 (pt) 2021-05-25
AU2002218262B2 (en) 2005-09-29
NO20031833L (no) 2003-04-24
EP1332137B1 (de) 2006-03-29
CZ20031152A3 (en) 2004-04-14
US20040023976A1 (en) 2004-02-05
CZ303944B6 (cs) 2013-07-10
HU229106B1 (en) 2013-07-29
CN1622808A (zh) 2005-06-01
HUP0301512A2 (hu) 2003-11-28
WO2002034727A3 (en) 2003-03-27
RU2301066C2 (ru) 2007-06-20
ES2260317T3 (es) 2006-11-01
WO2002034727A2 (en) 2002-05-02
BRPI0114870B1 (pt) 2020-06-16
PT1332137E (pt) 2006-07-31
NZ525254A (en) 2006-02-24
CY1105055T1 (el) 2010-03-03
IL155029A0 (en) 2003-10-31
NO20031833D0 (no) 2003-04-24
BR0114870A (pt) 2004-02-17
US6958335B2 (en) 2005-10-25
ZA200302155B (en) 2004-04-22
HK1058193A1 (en) 2004-05-07
NO324948B1 (no) 2008-01-07
JP4386635B2 (ja) 2009-12-16

Similar Documents

Publication Publication Date Title
ATE321556T1 (de) Behandlung gastrointestinaler stroma-tumoren
HK1028599A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
IL177005A0 (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
HK1072192A1 (en) Treatment of rheumatoid arthritis using imatinib
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
WO2004103374A3 (en) Imatinib combinations for head and neck cancers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DANA-FARBER CANCER INSTITUTE, INC., BOSTON, MA, US

Owner name: NOVARTIS AG, BASEL, CH

Owner name: OREGON HEALTH & SCIENCE UNIVERSITY, PORTLAND, , US

Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BOSTON, US

8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN